StemCell Therapy

KING OF PRUSSIA, Pa., July 9, 2020 /PRNewswire/ --Global biotherapeutics leader CSL Behring today announced the recipients of its 2020 Professor Heimburger Awardfor coagulation research just ahead of the first ever virtual congress of the International Society on Thrombosis and Hemostasis (ISTH).

The annual global Professor Heimburger Awards program recognizes the clinical and/or preclinical research of emerging coagulation specialists who are driven to improve the care of patients with bleeding disorders.The program demonstrates the company's continuing promise to support pioneering research by providing a 20,000 (~$22,500) research grant annually, to each of five recipients. This year's recipients are:

"Our leadership in hemophilia and other bleeding disorders starts with innovative science and extends beyond what is happening in our own labs or product portfolio to advance research and patient care across the globe," said Antti Kourula, Vice President, Hematology Therapeutic Area, CSL Behring."We look forward to the exciting research the Heimburger Awards supports."

In addition, CSL Behring will highlight its continued commitment to scientific research and innovation by participating as a Gold level sponsor at ISTH 2020 Virtual Congress. During the Congress, CSL Behring will host two symposia and two product theaters, along with supporting eight posters. (Full abstracts may be reviewed at https://abstracts.isth.org/)

CSL Behring Supported Symposia & Product Theaters (Tuesday, July 14, 2020)

CSL Behring Supported Posters

About the CSL Behring Professor Heimburger AwardsProfessor Norbert Heimburger was an employee of CSL Behring for more than 30 years and devoted his work to blood coagulation. One of his major contributions in this area was the development of virus-safe plasma products based on pasteurization, a development that led CSL Behring to produce the world's first virus-inactivated factor VIII concentrate to treat patients with hemophilia. More information about the Professor Heimburger Awards, including application information for 2021 can be found at: https://www.cslbehring.com/r-and-d/awards-and-grants/professor-heimburger-award

About CSL BehringCSL Behringis a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, anddelivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita CSLBehring.com/vita and follow us on Twitter.com/CSLBehring.

SOURCE CSL Behring

Link:
CSL Behring Announces Professor Heimburger Awards in Advance of ISTH 2020 Virtual Congress - PRNewswire

This entry was posted on July 10, 2020 at 1:44 pm and is filed under Personalized Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |